Press Releases Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.06 ^USD	0.00%		-9.40%	+22.54%

Apr. 24	Karyopharm Therapeutics Inc. Announces Presentations in Endometrial Cancer and Myelofibrosis At the 2024 American Society of Clinical Oncology Annual Meeting	CI
Mar. 13	Transcript : Karyopharm Therapeutics Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 09:00 AM

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting	Apr. 25	AQ
Karyopharm Therapeutics : April 19, 2024	Apr. 19	PU
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Apr. 01	PR
Karyopharm to Participate at Barclays 26th Annual Global Healthcare and Leerink Partners Global Biopharma Conferences	Mar. 06	PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Mar. 04	AQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 01	PR
Karyopharm Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress	Mar. 01	AQ
Karyopharm Therapeutics: Q4 Earnings Snapshot	Feb. 29	AQ
Karyopharm to Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024	Feb. 22	PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 01	PR
Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives	Jan. 08	PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Jan. 03	AQ
Karyopharm to Present at 42nd Annual J.P. Morgan Healthcare Conference	Jan. 03	PR
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jan. 02	PR
Karyopharm Shares Data at ASH 2023 Showing Strong SVR and TSS Durability Observed from Phase 1 Study of Selinexor 60mg and Ruxolitinib in JAK Inhibitor -Naive Myelofibrosis Patients, with no SVR or TSS Progressions Observed As of the Data Cutoff(1)	Dec. 11	AQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)	Dec. 04	AQ
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Dec. 01	PR
Karyopharm to Participate at Upcoming Investor Conferences	Nov. 08	PR
Karyopharm Announces New Preliminary Data in Overall Survival in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer	Nov. 07	AQ
Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition	Nov. 03	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Karyopharm Therapeutics Inc.

Equities

KPTI

US48576U1060

Press Releases

Filters